EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer

András Horváth, Celia Blasszauer, Ida Komka, Dániel Reibl, Boris Hadaschik, Tamás Fazekas, Pawel Rajwa iD, Àron Soós, Anikó Valikovics, Péter Nyirády, Tibor Szarvas

The Prostate · 2025-09 · 85 (12) · 1151-1154

DOI: 10.1002/pros.24923 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Prostate, online erschienen am 08.06.2025. Verfasst von András Horváth und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Benzamides, Prostatic Neoplasms, Castration-Resistant, Phenylthiohydantoin, Androstenes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While their indications overlap, no clinical trials have compared abiraterone and enzalutamide for overall survival (OS) in mCRPC.

Methods

A large, country‐wide health insurance database (2013‐2023) was assessed for the OS comparison between abiraterone and enzalutamide.

Results

Overall, 3497 patients were identified with first‐ ( n = 2215) or second‐line ( n = 1282) abiraterone or enzalutamide treatment (only 66 received both drugs sequentially). Enzalutamide‐treated patients had longer OS both in the first‐ (HR:0.84; 95%CI:0.74‐0.96; p = 0.008) and the second‐line setting (HR:0.88; 95%CI:0.78‐0.99; p = 0.043), respectively.

Conclusions

This health insurance‐registry‐based study suggests that, in the real‐world mCRPC setting, enzalutamide is superior to abiraterone in terms of OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzamidesProstatic Neoplasms, Castration-ResistantPhenylthiohydantoinAndrostenesAntineoplastic AgentsHumansMaleNitrilesAgedMiddle AgedAged, 80 and overSurvival RateNeoplasm MetastasisRegistries

Stichwörter der Autor:innen

ADTARPIabirateroneandrogen deprivation therapyantiandrogenenzalutamidemCRPCprostate cancerreal‐world

Substanzen

enzalutamideNitrilesBenzamidesabirateronePhenylthiohydantoinAndrostenesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Urology, Semmelweis University, Budapest, Hungary.
  • MedicalScan Ltd., Budapest, Hungary.
  • Department of Urology, University of Duisburg-Essen, Essen, Germany.
  • Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Austria.
  • Second Department of Urology, Centre of Postgraduate Medical Education, Warsaw, Poland.

ORCID-Profile: Pawel Rajwa

Zitieren

APA

Horváth, A., Blasszauer, C., Komka, I., Reibl, D., Hadaschik, B., Fazekas, T., Rajwa, P., Soós, À., Valikovics, A., Nyirády, P., & Szarvas, T. (2025). Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer. The Prostate, 85(12), 1151-1154. https://doi.org/10.1002/pros.24923

Vancouver

Horváth A, Blasszauer C, Komka I, Reibl D, Hadaschik B, Fazekas T, et al. Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer. The Prostate. 2025;85(12):1151-1154. doi:10.1002/pros.24923

BibTeX
@article{Horvth2025,
  author = {Horváth, András and Blasszauer, Celia and Komka, Ida and Reibl, Dániel and Hadaschik, Boris and Fazekas, Tamás and Rajwa, Pawel and Soós, Àron and Valikovics, Anikó and Nyirády, Péter and Szarvas, Tibor},
  title = {Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer},
  journal = {The Prostate},
  year = {2025},
  volume = {85},
  number = {12},
  pages = {1151--1154},
  doi = {10.1002/pros.24923}
}
Kostenlos starten →